BiotechTube
TAE Life Sciences

TAE Life Sciences

Irvine, United States
taelifesciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

TAE Life Sciences is pioneering the clinical and commercial development of Boron Neutron Capture Therapy (BNCT), a two-component targeted radiotherapy. The company is building an integrated platform comprising a boron-10 drug and the Alphabeam™ in-hospital neutron generator to treat recurrent, invasive, and metastatic cancers. As a pre-revenue, private company, TAE Life Sciences is advancing its technology through development and regulatory pathways, targeting a significant unmet need in oncology with a potentially curative, single-session treatment. Its success hinges on clinical validation, regulatory approval, and establishing a new treatment paradigm within radiation oncology.

Oncology

Technology Platform

Integrated Boron Neutron Capture Therapy (BNCT) platform combining a tumor-targeting boron-10 drug with a compact, in-hospital accelerator-based neutron source (Alphabeam™ Neutron System) to enable precise, biologically targeted radiotherapy.

Funding History

1
Total raised:$30M
Series A$30M

Opportunities

BNCT addresses a large unmet need in recurrent and treatment-resistant cancers, representing a multi-billion dollar market segment.
The compact, hospital-based neutron system overcomes the major historical barrier of reactor dependency, enabling broader clinical adoption.
The platform's dual-component nature allows for expansion into multiple solid tumor types through development of new boron-delivery drugs.

Risk Factors

The company faces significant technical risk in co-developing and integrating a novel drug and complex medical device.
Regulatory pathways for this combined modality are novel and uncertain.
High capital cost of the neutron system may limit hospital adoption, and commercial success depends on demonstrating superior clinical outcomes in a competitive oncology landscape.

Competitive Landscape

BNCT is a niche within targeted radiotherapy with few advanced competitors. Other companies, primarily in Japan (e.g., Stella Pharma, Sumitomo Heavy Industries) and Europe, are also developing BNCT, with some systems already approved in Japan. TAE Life Sciences differentiates with its compact, accelerator-based system designed for hospital integration. It also competes indirectly with other advanced radiation modalities (e.g., proton therapy, targeted radionuclide therapy) and next-generation systemic therapies.

More companies in Radiopharmaceuticals →More companies in United States →